Sanofi's Financial Triumph in Q1 2025

Sanofi SA announced a remarkable achievement in the first quarter of fiscal year 2025, with net sales climbing by 10.8% year-over-year, or 9.7% at a constant exchange rate (CER), to an impressive €9.9 billion.

Profitability on the Rise

The company's financial health shone brightly, reporting a net income of €1.8 billion under the International Financial Reporting Standards (IFRS), alongside an IFRS earnings per share (EPS) of €1.52. Notably, business net income saw a 15.9% increase, or 14.5% at CER, reaching €2.2 million, with business EPS growing by 17%, or 15.7% at CER, to €1.79. The first quarter also witnessed a 14.2% surge in gross profit, or 11.3% at CER, totaling €7.7 billion.

Leadership's Confidence

"Our robust sales growth and business EPS performance reinforce our confidence in the 2025 guidance, given the current external environment," stated CEO Paul Hudson, highlighting the company's optimistic outlook.